Cargando…
LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients
BACKGROUND: A combination treatment of interferon and ribavirin is the standard and the commonly used treatment for chronic hepatitis C (CHC). Developing noninvasive tests like serum indicators that can predict treatment outcome at an early stage of therapy is beneficial for individualized treatment...
Autores principales: | Zou, Xia, Chi, Xiumei, Pan, Yu, Du, Dongning, Sun, Haibo, Matsuda, Atsushi, Li, Wei, Kuno, Atsushi, Zhang, Xinxin, Narimatsu, Hisashi, Niu, Junqi, Zhang, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276098/ https://www.ncbi.nlm.nih.gov/pubmed/25593566 http://dx.doi.org/10.1186/1559-0275-11-44 |
Ejemplares similares
-
A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis
por: Kuno, Atsushi, et al.
Publicado: (2013) -
LECT2 Protects Nile Tilapia (Oreochromis niloticus) Against Streptococcus agalatiae Infection
por: Li, Qi, et al.
Publicado: (2021) -
Loss of bound zinc facilitates amyloid fibril formation of leukocyte-cell-derived chemotaxin 2 (LECT2)
por: Ha, Jeung-Hoi, et al.
Publicado: (2021) -
Prognostic value of LECT2 and relevance to immune infiltration in hepatocellular carcinoma
por: Qin, Jiangfeng, et al.
Publicado: (2022) -
Data on functional characterization of LECT2 from Lampetra japonica
por: Wang, Zhiliang, et al.
Publicado: (2018)